Bit Bio Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Bit Bio's estimated annual revenue is currently $24.8M per year.(i)
  • Bit Bio's estimated revenue per employee is $155,000

Employee Data

  • Bit Bio has 160 Employees.(i)
  • Bit Bio grew their employee count by 37% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Bit Bio is an award-winning human synthetic biology enterprise. Our mission is to code cells to advance the wellbeing of humanity. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy. Collaboration is at the heart of Bit Bio. We are empirical, highly ambitious and driven by a common purpose.

keywords:N/A

N/A

Total Funding

160

Number of Employees

$24.8M

Revenue (est)

37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Bit Bio News

2022-04-20 - IPL 2022: RCB organize Glenn Maxwell’s wedding party in bio-bubble, Virat Kohli shakes a leg

Owing to his wedding, Maxwell entered the RCB bio-bubble a bit late and also missed a few games. In any case, he wouldn't have played before...

2021-11-08 - Bit.bio secures $103M

Bit.bio has raised a $103 million Series B from investors including Arch Ventures, Foresite Capital and Charles River Laboratories. Based in San Francisco and the UK, the company is a developer of cell coding technology intended to discover new cell therapies. View round

2021-11-08 - U.K.-based bit.bio secures €89.1M to expedite gene engineering technology to fight diseases

Cambridge, UK-based bit.bio, a human cell coding company, raised $103M (approx €89.1M) in a Series B round of funding. Arch Ventures, Charles River Laboratories, Foresite Capital, Resilience, Metaplanet, Puhua Capital, and Tencent participated in the funding round.A new, prominent Board of Direc ...

2021-11-05 - bit.bio raises $103 million in first close of Series B financing

bit.bio raises $103 million in first close of Series B financing 05-11-2021 Today bit.bio announces the first close of its Series B financing of $103 million. The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM. New and e ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.5M16131%$366.3M
#2
$25M16153%$152M
#3
$37.2M1614%N/A
#4
$32.1M1628%N/A
#5
$18.2M16312%$153M